A Phase 2 interventional study of insulin degludec and insulin degludec in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 33 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is one of 4 that started in 2008, is one of 3 in phase 2, and was the 13th registered.
3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 178 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 47th largest by enrollment of the 149 interventional ones that give a count, is one of 19 that started in 2008, is one of 8 in phase 2, and was the 35th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.
3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 178 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec · Drug: insulin aspart
Drug: insulin degludec · Drug: insulin aspart
Drug: insulin glargine · Drug: insulin aspart
Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
Treat-to-target dose titration scheme, injection s.c., once daily
Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
Change in Glycosylated Haemoglobin (HbA1c)
Change from baseline in HbA1c after 16 weeks of treatment
Time frame: Week 0, Week 16
Change in Fasting Plasma Glucose (FPG)
Change from baseline in FPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment
Time frame: Week 0, Week 16
Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)
Estimate of the overall mean of SMPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast.
Time frame: Week 16
Rate of Major and Minor Hypoglycaemic Episodes
Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Week 0 to Week 16 + 5 days follow up
Rate of Nocturnal Major and Minor Hypoglycaemic Episodes
Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded).
Time frame: Week 0 to Week 16 + 5 days follow up
Rate of Treatment Emergent Adverse Events (AEs)
Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
Time frame: Week 0 to Week 16 + 5 days follow up
Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)
Laboratory values at screening (Week -1) and at Week 16
Time frame: Week -1, Week 16
Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)
Laboratory values at screening (Week -1) and at Week 16
Time frame: Week -1, Week 16
Laboratory Safety Parameters (Biochemistry): Serum Creatinine
Laboratory values at screening (Week -1) and at Week 16
Time frame: Week -1, Week 16
Vital Signs: Diastolic BP (Blood Pressure)
Values at baseline (Week 0) and at Week 16
Time frame: Week 0, Week 16
Vital Signs: Systolic BP (Blood Pressure)
Values at baseline (Week 0) and at Week 16
Time frame: Week 0, Week 16
Vital Signs: Pulse
Values at baseline (Week 0) and at Week 16
Time frame: Week 0, Week 16
Physical Examination
Physical examination was performed at screening (week -1), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.
Time frame: Week -1, Week 8, Week 16
A total of 28 centres participated: Australia (5), Germany (6), Norway (6), Sweden (5) and United States (6).
| Milestone | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Started | 60 | 59 | 59 |
| Exposed | 60 | 59 | 59 |
| Completed | 55 | 52 | 52 |
| Not completed | 5 | 7 | 7 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Protocol violation | 1 | 2 | 1 |
| Withdrew: Lack of efficacy | 2 | 1 | 0 |
| Withdrew: Unclassified | 2 | 2 | 5 |
Change from baseline in HbA1c after 16 weeks of treatment
| percentage of glycosylated haemoglobin | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -0.54 ± 0.78 | -0.57 ± 0.76 | -0.62 ± 0.68 |
Change from baseline in FPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment
| mmol/L | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -2.06 ± 5.17 | -1.60 ± 4.66 | -0.54 ± 4.36 |
Estimate of the overall mean of SMPG (expressed in mmol/L, 1 mg/dL = 18times mmol/L) after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, bedtime, at 4 am and before breakfast.
| mmol/L | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) | 9.27 ± 0.30 | 9.56 ± 0.30 | 9.04 ± 0.30 |
Rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.
| Episodes/100 years of patient exposure | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Major | 46 | 41 | 36 |
| Minor | 5838 | 5305 | 6637 |
Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 06:00 (excluded).
| Episodes/100 years of patient exposure | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Major | 17 | 12 | 18 |
| Minor | 769 | 546 | 1082 |
Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
| Events/100 years of patient exposure | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Adverse events (AEs) | 653 | 874 | 914 |
| Serious AEs | 6 | 12 | 6 |
| Severe AEs | 6 | 29 | 6 |
| Moderate AEs | 202 | 246 | 397 |
| Mild AEs | 445 | 599 | 511 |
| Fatal AEs | 0 | 0 | 0 |
Laboratory values at screening (Week -1) and at Week 16
| IU/L | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Week -1 , N=60, 59, 59 | 25.5 ± 11.3 | 22.7 ± 11.1 | 23.1 ± 10.2 |
| Week 16 , N=55, 53, 54 | 25.0 ± 12.0 | 21.2 ± 8.0 | 23.1 ± 13.0 |
Laboratory values at screening (Week -1) and at Week 16
| IU/L | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Week -1, N=60, 59, 59 | 22.8 ± 7.4 | 21.7 ± 7.0 | 23.3 ± 11.3 |
| Week 16, N=55, 53, 54 | 23.3 ± 8.8 | 21.6 ± 8.5 | 23.9 ± 9.4 |
Laboratory values at screening (Week -1) and at Week 16
| umol/L | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Week -1 , N=60, 59, 59 | 77.2 ± 12.6 | 76.6 ± 12.8 | 77.6 ± 13.3 |
| Week 16 , N=55, 53, 54 | 77.2 ± 14.1 | 75.9 ± 13.0 | 77.9 ± 14.5 |
Values at baseline (Week 0) and at Week 16
| mmHg | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Week 0 (Baseline), N=60, 59, 59 | 76 ± 8 | 75 ± 10 | 74 ± 9 |
| Week 16, N=60, 57, 57 | 76 ± 10 | 75 ± 10 | 74 ± 7 |
Values at baseline (Week 0) and at Week 16
| mmHg | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Week 0 (Baseline), N=60, 59, 59 | 124 ± 15 | 126 ± 16 | 124 ± 16 |
| Week 16, N=60, 57, 57 | 122 ± 14 | 125 ± 14 | 123 ± 15 |
Values at baseline (Week 0) and at Week 16
| beats/minute | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Week 0 (Baseline), N=60, 59, 59 | 74 ± 10 | 72 ± 9 | 73 ± 10 |
| Week 16, N=60, 57, 57 | 74 ± 12 | 72 ± 11 | 72 ± 12 |
Physical examination was performed at screening (week -1), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.
No measurements were reported for this outcome.
Collected over The adverse events were collected in a time frame of 16 weeks + 5 days follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SIBA (D) | — | 1/60 (1.7%) | 31/60 (51.7%) |
| SIBA (E) | — | 2/59 (3.4%) | 42/59 (71.2%) |
| IGlar | — | 1/59 (1.7%) | 31/59 (52.5%) |
| Event | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| Abdominal distensionGastrointestinal disorders | 0/60 | 1/59 | 0/59 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/60 | 0/59 | 1/59 |
| Hypoglycaemic unconsciousnessMetabolism and nutrition disorders | 0/60 | 1/59 | 0/59 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/60 | 0/59 | 0/59 |
| Event | SIBA (D) | SIBA (E) | IGlar |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 14/60 | 24/59 | 15/59 |
| HeadacheNervous system disorders | 10/60 | 16/59 | 10/59 |
| Upper respiratory tract infectionInfections and infestations | 3/60 | 2/59 | 7/59 |
| InfluenzaInfections and infestations | 4/60 | 6/59 | 3/59 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/60 | 6/59 | 2/59 |
| Back painMusculoskeletal and connective tissue disorders | 6/60 | 3/59 | 2/59 |
| NauseaGastrointestinal disorders | 2/60 | 5/59 | 2/59 |
| DiarrhoeaGastrointestinal disorders | 1/60 | 2/59 | 4/59 |
| SinusitisInfections and infestations | 1/60 | 0/59 | 4/59 |
| ConstipationGastrointestinal disorders | 1/60 | 3/59 | 1/59 |
| Age, Continuous(years) | SIBA (D) | SIBA (E) | IGlar | Total |
|---|---|---|---|---|
| Mean | 45.6 ± 12.5 | 44.5 ± 12.7 | 47.2 ± 13.5 | 45.8 ± 12.8 |
| Gender(Participants) | SIBA (D) | SIBA (E) | IGlar | Total |
|---|---|---|---|---|
| Female | 23 | 22 | 27 | 72 |
| Male | 37 | 37 | 32 | 106 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | SIBA (D) | SIBA (E) | IGlar | Total |
|---|---|---|---|---|
| Mean | 8.5 ± 1.0 | 8.4 ± 0.9 | 8.3 ± 0.8 | 8.4 ± 0.9 |
| Fasting plasma glucose (FPG)(mmol/L) | SIBA (D) | SIBA (E) | IGlar | Total |
|---|---|---|---|---|
| Mean | 10.3 ± 4.8 | 9.9 ± 3.3 | 9.5 ± 3.8 | 9.9 ± 4.0 |
The record gives a start of Jan 2008, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 7 years 5 months after primary completion. A results delay was requested in Nov 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine